Cargando…

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction

AIMS: Ivabradine and sacubitril/valsartan are second‐line therapies for patients with heart failure and reduced ejection fraction (HFrEF) based on guideline recommendations. We aimed to evaluate the synergistic effects of these two medications. METHODS AND RESULTS: Patients' data were extracted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Ying‐Hsiang, Lin, Po‐Lin, Chiou, Wei‐Ru, Huang, Jin‐Long, Lin, Wen‐Yu, Liao, Chia‐Te, Chung, Fa‐Po, Liang, Huai‐Wen, Hsu, Chien‐Yi, Chang, Hung‐Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006660/ https://www.ncbi.nlm.nih.gov/pubmed/33410280 http://dx.doi.org/10.1002/ehf2.13182

Ejemplares similares

Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy
por: Huang, Hsin‐Ti, et al.
Publicado: (2022)

Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan
por: Hsu, Chien-Yi, et al.
Publicado: (2022)

The association between ivabradine and adverse cardiovascular events in acute decompensated HFrEF patients
por: Liao, Chia‐Te, et al.
Publicado: (2021)

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)

Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
por: McMurray, John J V, et al.
Publicado: (2018)

Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
por: Liu, Rex C.
Publicado: (2018)

ECG Monitoring of Reactions to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction
por: Kang, Min-Kyung
Publicado: (2020)

The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
por: Selvaraj, Senthil, et al.
Publicado: (2021)

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
por: Khan, Muhammad Nauman, et al.
Publicado: (2023)

Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis
por: Fu, Sha, et al.
Publicado: (2021)

Renal protective effect of sacubitril/valsartan in patients with heart failure
por: Hsieh, Hui-Ling, et al.
Publicado: (2021)

Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients
por: Cheang, Iokfai, et al.
Publicado: (2022)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
por: Moon, Mi‐Gil, et al.
Publicado: (2021)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
por: Maggioni, Aldo P., et al.
Publicado: (2022)

Ivabradine in heart failure patients with reduced ejection fraction and history of paroxysmal atrial fibrillation
por: Lin, Yu‐Sheng, et al.
Publicado: (2022)

Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real‐world study
por: Wang, Chen, et al.
Publicado: (2023)

Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials
por: Yu, Wanqian, et al.
Publicado: (2022)

Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination
por: Kaplinsky, Edgardo
Publicado: (2016)

Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction
por: Vitale, Giuseppe, et al.
Publicado: (2019)

Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction
por: Landolfo, Matteo, et al.
Publicado: (2020)

Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial
por: Mann, Douglas L., et al.
Publicado: (2020)

Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
por: Lee, Seonhwa, et al.
Publicado: (2020)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Gori, Mauro, et al.
Publicado: (2021)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
por: Greene, Stephen J., et al.
Publicado: (2021)

Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction
por: Fernandes, Amanda D.F., et al.
Publicado: (2021)

Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction
por: Bolla, Giovanni Battista, et al.
Publicado: (2022)

Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction
por: Wang, Youmeng, et al.
Publicado: (2022)

The Effect of Sacubitril-Valsartan on Ventricular Arrhythmia Burden in Patients With Heart Failure With Reduced Ejection Fraction
por: Medeiros, Paulo, et al.
Publicado: (2023)

Effects of sacubitril-valsartan on heart failure patients with mid-range ejection fractions: A systematic review and meta-analysis
por: Qin, Jianbin, et al.
Publicado: (2022)

Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction
por: Kobalava, Zhanna, et al.
Publicado: (2016)

Sacubitril/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction
por: Giallauria, Francesco, et al.
Publicado: (2020)

Effects of Sacubitril/Valsartan on the Right Ventricular Arterial Coupling in Patients with Heart Failure with Reduced Ejection Fraction
por: Masarone, Daniele, et al.
Publicado: (2020)

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
por: Polito, Maria Vincenza, et al.
Publicado: (2020)

Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
por: Nordberg Backelin, Charlotte, et al.
Publicado: (2020)

Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction
por: Jackson, Alice M, et al.
Publicado: (2021)

Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum
por: Gallo, Giovanna, et al.
Publicado: (2021)

Reduction of Pulmonary Hypertension After Transition to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction
por: Burgdorf, Christof, et al.
Publicado: (2021)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
por: Lund, Lars H., et al.
Publicado: (2021)

The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients
por: Oh, Ji‐Hye, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4elb9ba32ml6lrsfei85c9uhr2